Details of the Drug Combination

General Information of Drug Combination (ID: DCHSM0H)

Drug Combination Name
Etoposide GSK525762
Indication
Disease Entry Status REF
Ovarian endometrioid adenocarcinoma Investigative [1]
Component Drugs Etoposide   DMNH3PG GSK525762   DMPAWBN
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: A2780
Zero Interaction Potency (ZIP) Score: 8.53
Bliss Independence Score: 7.5
Loewe Additivity Score: 3.83
LHighest Single Agent (HSA) Score: 8.92

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Etoposide
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [2]
Adult acute monocytic leukemia N.A. Approved [2]
Adult kidney Wilms tumor N.A. Approved [2]
Beckwith-Wiedemann syndrome N.A. Approved [2]
Childhood kidney Wilms tumor N.A. Approved [2]
Hamartoma N.A. Approved [2]
Kidney neoplasm N.A. Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Plasma cell myeloma 2A83.1 Approved [2]
Small-cell lung cancer 2C25.Y Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Testicular cancer 2C80 Approved [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [5]
Neuroblastoma 2D11.2 Investigative [2]
Etoposide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [29]
------------------------------------------------------------------------------------
Etoposide Interacts with 8 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [30]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [31]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [32]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [33]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [34]
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [35]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [36]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [34]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DTP(s)
Etoposide Interacts with 9 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [37]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [37]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [8]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [38]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Metabolism [39]
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Metabolism [40]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Metabolism [41]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Metabolism [40]
Prostaglandin G/H synthase 2 (COX-2) DE492CE PGH2_HUMAN Metabolism [41]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DME(s)
Etoposide Interacts with 475 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Increases Expression [42]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [43]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases Expression [43]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Decreases Methylation [44]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Decreases Response To Substance [45]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [46]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Decreases Response To Substance [47]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [45]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Affects Transport [48]
DNA topoisomerase 2-alpha (TOP2A) OT6LPS08 TOP2A_HUMAN Decreases Response To Substance [49]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [50]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [51]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Increases ADR [52]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Decreases Response To Substance [53]
Tumor protein p73 (TP73) OT0LUO47 P73_HUMAN Increases Expression [9]
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial (CYP27B1) OTTK98BH CP27B_HUMAN Increases Expression [9]
Dihydropyrimidinase-related protein 4 (DPYSL4) OT3SBS2S DPYL4_HUMAN Increases Expression [10]
Copper chaperone for superoxide dismutase (CCS) OTXHT3QO CCS_HUMAN Increases Expression [10]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Increases Expression [10]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [10]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Increases Expression [10]
Integrin alpha-IIb (ITGA2B) OT4Y17PY ITA2B_HUMAN Increases Expression [10]
Ras-related protein R-Ras (RRAS) OTBBF28C RRAS_HUMAN Increases Expression [10]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [10]
Stomatin (STOM) OTC8R6EH STOM_HUMAN Increases Expression [10]
Cellular retinoic acid-binding protein 2 (CRABP2) OTY01V9G RABP2_HUMAN Increases Expression [10]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Increases Expression [10]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Increases Expression [10]
Galectin-7 (LGALS7) OTMSVI7R LEG7_HUMAN Increases Expression [10]
Rho GDP-dissociation inhibitor 2 (ARHGDIB) OT9PD6CS GDIR2_HUMAN Increases Expression [10]
Epithelial membrane protein 1 (EMP1) OTSZHUHQ EMP1_HUMAN Increases Expression [10]
Epithelial membrane protein 3 (EMP3) OTODMJ1D EMP3_HUMAN Increases Expression [10]
Protein ripply3 (RIPPLY3) OT1HK35I DSCR6_HUMAN Increases Expression [10]
Kinesin-like protein KIF1A (KIF1A) OT3JVEGV KIF1A_HUMAN Increases Expression [10]
Filamin-C (FLNC) OT3F8J6Y FLNC_HUMAN Increases Expression [10]
Immediate early response gene 5 protein (IER5) OTJPTXMD IER5_HUMAN Increases Expression [10]
Keratin, type II cytoskeletal 80 (KRT80) OTAU54U3 K2C80_HUMAN Increases Expression [10]
All-trans-retinol 13,14-reductase (RETSAT) OTC3AOPX RETST_HUMAN Increases Expression [10]
Mitochondria-eating protein (SPATA18) OTOEHTHU MIEAP_HUMAN Increases Expression [10]
Tumor necrosis factor receptor superfamily member 14 (TNFRSF14) OTB82PFO TNR14_HUMAN Increases Expression [10]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Increases Expression [10]
Roundabout homolog 3 (ROBO3) OTPVG40S ROBO3_HUMAN Increases Expression [10]
Neuronal PAS domain-containing protein 1 (NPAS1) OTZKO6ZN NPAS1_HUMAN Increases Expression [10]
Ankyrin repeat domain-containing protein 10 (ANKRD10) OTIZ2VK8 ANR10_HUMAN Decreases Expression [10]
Serine/threonine-protein kinase PLK2 (PLK2) OTKMJXJ8 PLK2_HUMAN Increases Expression [10]
Solute carrier family 2, facilitated glucose transporter member 6 (SLC2A6) OTVUZCLG GTR6_HUMAN Increases Expression [10]
Glutaminase liver isoform, mitochondrial (GLS2) OT08MSHL GLSL_HUMAN Increases Expression [10]
Endothelial protein C receptor (PROCR) OTRHED17 EPCR_HUMAN Increases Expression [10]
Fatty acid desaturase 3 (FADS3) OT9RVXGE FADS3_HUMAN Increases Expression [10]
Catalase (CAT) OTHEBX9R CATA_HUMAN Increases Activity [54]
NADH-ubiquinone oxidoreductase chain 4 (ND4) OT4RQVAA NU4M_HUMAN Increases Expression [42]
Nitric oxide synthase, inducible (NOS2) OTKKIOJ1 NOS2_HUMAN Increases Expression [42]
Transcription factor A, mitochondrial (TFAM) OTXXV5V7 TFAM_HUMAN Increases Expression [42]
TP53-binding protein 1 (TP53BP1) OTL8879S TP53B_HUMAN Increases Expression [42]
Peroxisome proliferator-activated receptor gamma coactivator 1-beta (PPARGC1B) OTN6FKCB PRGC2_HUMAN Increases Expression [42]
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A) OTHCDQ22 PRGC1_HUMAN Increases Expression [42]
Calsequestrin-2 (CASQ2) OT09MNQ8 CASQ2_HUMAN Decreases Expression [11]
Telethonin (TCAP) OTQQMJ94 TELT_HUMAN Decreases Expression [11]
LIM domain-binding protein 3 (LDB3) OTGQL1AM LDB3_HUMAN Decreases Expression [11]
Creatine kinase M-type (CKM) OTME0KO7 KCRM_HUMAN Decreases Expression [11]
Glutathione peroxidase 1 (GPX1) OTE2O72Q GPX1_HUMAN Increases Expression [11]
Myosin light chain 3 (MYL3) OTKD3RSX MYL3_HUMAN Decreases Expression [11]
Keratin, type I cytoskeletal 19 (KRT19) OTDGDQ75 K1C19_HUMAN Increases Expression [11]
Calmodulin-1 (CALM2) OTNYA92F CALM1_HUMAN Increases Expression [11]
Myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MYL2) OT78PC0C MLRV_HUMAN Decreases Expression [11]
Glycogen phosphorylase, muscle form (PYGM) OTWLVWTV PYGM_HUMAN Decreases Expression [11]
Dystrophin (DMD) OTD21T5J DMD_HUMAN Decreases Expression [11]
Myosin-7 (MYH7) OT4Z9T8N MYH7_HUMAN Decreases Expression [11]
Leukemia inhibitory factor (LIF) OTO46S5S LIF_HUMAN Increases Expression [11]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Expression [11]
Ankyrin-1 (ANK1) OTU79URK ANK1_HUMAN Increases Expression [11]
Desmin (DES) OTI09KBW DESM_HUMAN Decreases Expression [11]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [11]
CCN family member 2 (CCN2) OTC39NSU CCN2_HUMAN Increases Expression [11]
Sodium/calcium exchanger 1 (SLC8A1) OT787VRN NAC1_HUMAN Decreases Expression [11]
Thrombospondin-4 (THBS4) OTA1T9KK TSP4_HUMAN Increases Expression [11]
Gap junction alpha-5 protein (GJA5) OTRMZVO6 CXA5_HUMAN Decreases Expression [11]
Vasopressin V1a receptor (AVPR1A) OTKR8AFL V1AR_HUMAN Increases Expression [11]
Sodium/potassium-transporting ATPase subunit alpha-2 (ATP1A2) OTCF8OWW AT1A2_HUMAN Decreases Expression [11]
cAMP-dependent protein kinase catalytic subunit PRKX (PRKX) OTDAC6Z0 PRKX_HUMAN Increases Expression [11]
Stanniocalcin-1 (STC1) OTGVVXYF STC1_HUMAN Increases Expression [11]
Myomesin-2 (MYOM2) OTD2UOXW MYOM2_HUMAN Decreases Expression [11]
Actin, alpha skeletal muscle (ACTA1) OTOVGLPG ACTS_HUMAN Decreases Expression [11]
Iroquois-class homeodomain protein IRX-4 (IRX4) OT0TV6WK IRX4_HUMAN Decreases Expression [11]
Arginase-2, mitochondrial (ARG2) OTCPI0E8 ARGI2_HUMAN Decreases Expression [11]
Cytochrome c oxidase subunit 6A2, mitochondrial (COX6A2) OTQR5SXD CX6A2_HUMAN Decreases Expression [11]
Pro-neuregulin-1, membrane-bound isoform (NRG1) OTZO6F1X NRG1_HUMAN Increases Expression [11]
Dual specificity protein phosphatase 4 (DUSP4) OT6WAO12 DUS4_HUMAN Increases Expression [11]
Krueppel-like factor 5 (KLF5) OT1ABI9N KLF5_HUMAN Increases Expression [11]
Four and a half LIM domains protein 2 (FHL2) OT0OAYWT FHL2_HUMAN Decreases Expression [11]
Transmembrane glycoprotein NMB (GPNMB) OTB7KQKV GPNMB_HUMAN Increases Expression [11]
Periostin (POSTN) OTWP62UA POSTN_HUMAN Increases Expression [11]
kinase isozyme 1, mitochondrial (PDK1) OTMABK9Z PDK1_HUMAN Decreases Expression [11]
kinase isozyme 4, mitochondrial (PDK4) OTCMHMBZ PDK4_HUMAN Increases Expression [11]
PDZ and LIM domain protein 3 (PDLIM3) OTVXQC81 PDLI3_HUMAN Increases Expression [11]
Nebulin-related-anchoring protein (NRAP) OTO6H3YF NRAP_HUMAN Decreases Expression [11]
Sodium channel subunit beta-4 (SCN4B) OT3JSUWO SCN4B_HUMAN Increases Expression [11]
Actin-binding Rho-activating protein (ABRA) OTBQ2C1J ABRA_HUMAN Increases Expression [11]
Transient receptor potential cation channel subfamily V member 1 (TRPV1) OTHHDR03 TRPV1_HUMAN Increases Expression [11]
Ryanodine receptor 2 (RYR2) OT0PF19E RYR2_HUMAN Decreases Expression [11]
Small conductance calcium-activated potassium channel protein 2 (KCNN2) OTQVTMK5 KCNN2_HUMAN Decreases Expression [11]
Regulator of cell cycle RGCC (RGCC) OTYJMLWM RGCC_HUMAN Increases Expression [11]
Myotilin (MYOT) OTCEW5XW MYOTI_HUMAN Increases Expression [11]
Protein ATP1B4 (ATP1B4) OT2YC9GZ AT1B4_HUMAN Increases Expression [11]
Junctional adhesion molecule A (F11R) OTGHPAV6 JAM1_HUMAN Increases Expression [11]
Succinate dehydrogenase assembly factor 1, mitochondrial (SDHAF1) OTDG5VW7 SDHF1_HUMAN Decreases Expression [13]
Agrin (AGRN) OTWJENAZ AGRIN_HUMAN Increases Expression [12]
E3 ubiquitin-protein ligase TRIM38 (TRIM38) OT6SP1M9 TRI38_HUMAN Decreases Expression [13]
Torsin-1A (TOR1A) OTYCLGJU TOR1A_HUMAN Decreases Expression [13]
Etoposide-induced protein 2.4 homolog (EI24) OTD4NOYS EI24_HUMAN Increases Expression [12]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [55]
Tax1-binding protein 3 (TAX1BP3) OTQ6IB4T TX1B3_HUMAN Increases Expression [12]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB) OT9RDS3H IKKB_HUMAN Decreases Expression [56]
Proepiregulin (EREG) OTRM4NQY EREG_HUMAN Increases Expression [57]
Transcription factor EC (TFEC) OTUST8MR TFEC_HUMAN Decreases Expression [13]
Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK) OTLF4ZB1 IKKA_HUMAN Decreases Expression [56]
Protein phosphatase 1D (PPM1D) OT8NLZ9D PPM1D_HUMAN Increases Expression [58]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Increases Expression [59]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Increases Expression [60]
E3 ubiquitin-protein ligase RNF113A (RNF113A) OTR6N7HU R113A_HUMAN Decreases Expression [13]
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2) OT0KMIYQ RIPK2_HUMAN Increases Expression [59]
Krueppel-like factor 4 (KLF4) OT4O9RQW KLF4_HUMAN Increases Expression [61]
Forkhead box protein O3 (FOXO3) OTHXQG4P FOXO3_HUMAN Increases Phosphorylation [62]
Cytoplasmic protein NCK2 (NCK2) OTUYPF55 NCK2_HUMAN Decreases Expression [12]
Protein regulator of cytokinesis 1 (PRC1) OTHD0XS0 PRC1_HUMAN Decreases Expression [12]
Mitotic checkpoint serine/threonine-protein kinase BUB1 (BUB1) OT80DZMT BUB1_HUMAN Decreases Expression [63]
HMG box-containing protein 1 (HBP1) OTDPGGDV HBP1_HUMAN Decreases Expression [13]
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B) OT8KME51 BUB1B_HUMAN Decreases Expression [63]
Cell division control protein 45 homolog (CDC45) OT6NNLOD CDC45_HUMAN Decreases Expression [63]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [64]
Kinesin-like protein KIF20A (KIF20A) OTXOQHE0 KI20A_HUMAN Decreases Expression [13]
Myelin protein zero-like protein 1 (MPZL1) OTJSUUHR MPZL1_HUMAN Decreases Expression [13]
Serine/threonine-protein kinase Chk2 (CHEK2) OT8ZPCNS CHK2_HUMAN Increases Phosphorylation [65]
Aldehyde dehydrogenase 1A1 (ALDH1A1) OTCUWZKB AL1A1_HUMAN Increases Expression [61]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Expression [57]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases Expression [66]
Protransforming growth factor alpha (TGFA) OTPD1LL9 TGFA_HUMAN Increases Expression [57]
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Affects Expression [67]
Transferrin receptor protein 1 (TFRC) OT8ZPBDL TFR1_HUMAN Decreases Expression [61]
Ferritin light chain (FTL) OTYQA8A6 FRIL_HUMAN Increases Expression [61]
Metallothionein-2 (MT2A) OTHOACHD MT2_HUMAN Decreases Expression [16]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Decreases Expression [68]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Expression [51]
HLA class I histocompatibility antigen, A alpha chain (HLA-A) OTAH14LU HLAA_HUMAN Affects Expression [67]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Decreases Expression [57]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Acetylation [69]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Expression [43]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Phosphorylation [70]
Transcription factor Sp1 (SP1) OTISPT4X SP1_HUMAN Increases Phosphorylation [71]
High mobility group protein B1 (HMGB1) OT4B7CPF HMGB1_HUMAN Increases Secretion [72]
Annexin A4 (ANXA4) OTUCRYXL ANXA4_HUMAN Increases Expression [12]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [73]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [74]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Increases Expression [74]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Increases Degradation [75]
Cholesteryl ester transfer protein (CETP) OTAGPPOE CETP_HUMAN Increases Expression [76]
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) OTPWI88U CEAM1_HUMAN Increases Expression [12]
Translationally-controlled tumor protein (TPT1) OTHMTRJU TCTP_HUMAN Increases Expression [77]
Tissue factor (F3) OT3MSU3B TF_HUMAN Increases Expression [78]
HLA class I histocompatibility antigen, alpha chain E (HLA-E) OTX1CTFB HLAE_HUMAN Affects Expression [67]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Decreases Expression [63]
Protein C-ets-1 (ETS1) OT4LVGDN ETS1_HUMAN Increases Expression [56]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Increases Expression [57]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [79]
Syndecan-1 (SDC1) OTWKRVZC SDC1_HUMAN Increases Expression [12]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [63]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Decreases Expression [57]
rRNA 2'-O-methyltransferase fibrillarin (FBL) OTRODIE5 FBRL_HUMAN Affects Localization [80]
NADPH:adrenodoxin oxidoreductase, mitochondrial (FDXR) OTPDCK1F ADRO_HUMAN Increases Expression [12]
Brain-derived neurotrophic factor (BDNF) OTLGH7EW BDNF_HUMAN Increases Expression [81]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Decreases Expression [13]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Increases Expression [63]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Increases Expression [14]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Degradation [82]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [50]
Tripeptidyl-peptidase 2 (TPP2) OT91OVAU TPP2_HUMAN Affects Localization [83]
M-phase inducer phosphatase 1 (CDC25A) OTSLKKCO MPIP1_HUMAN Decreases Expression [13]
M-phase inducer phosphatase 3 (CDC25C) OTPQI71S MPIP3_HUMAN Decreases Expression [63]
Dual specificity protein kinase TTK (TTK) OTBY1Z5H TTK_HUMAN Decreases Expression [63]
DNA replication licensing factor MCM7 (MCM7) OT6FXC6K MCM7_HUMAN Decreases Expression [63]
Replication factor C subunit 1 (RFC1) OT3L5PK3 RFC1_HUMAN Decreases Expression [13]
Tumor necrosis factor receptor superfamily member 3 (LTBR) OT2HVZGV TNR3_HUMAN Increases Expression [59]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Decreases Expression [84]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [63]
Transcription factor ETV6 (ETV6) OTCZMG61 ETV6_HUMAN Increases Mutagenesis [85]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9) OTV9L89D TNFL9_HUMAN Increases Expression [12]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Increases Phosphorylation [86]
Caspase-2 (CASP2) OTUDYSPP CASP2_HUMAN Increases Expression [87]
RNA-binding protein 34 (RBM34) OTX3LUGI RBM34_HUMAN Decreases Expression [13]
DNA repair protein RAD52 homolog (RAD52) OT0OTDHI RAD52_HUMAN Increases Expression [88]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [62]
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3) OTI2OREX MP2K3_HUMAN Increases Expression [12]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Activity [89]
Stromal cell-derived factor 1 (CXCL12) OT2QX5LL SDF1_HUMAN Decreases Expression [90]
Iron-responsive element-binding protein 2 (IREB2) OT747D24 IREB2_HUMAN Decreases Expression [61]
Nuclear receptor-interacting protein 1 (NRIP1) OTIZOJQV NRIP1_HUMAN Decreases Expression [76]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [91]
Centromere protein F (CENPF) OT7AG0SW CENPF_HUMAN Decreases Expression [63]
CCAAT/enhancer-binding protein alpha (CEBPA) OTOM9OE4 CEBPA_HUMAN Decreases Expression [92]
DNA replication licensing factor MCM2 (MCM2) OTGGORIQ MCM2_HUMAN Decreases Expression [63]
LIM/homeobox protein Lhx2 (LHX2) OTK61NP8 LHX2_HUMAN Decreases Expression [13]
Serine/threonine-protein kinase Nek2 (NEK2) OT1H27HO NEK2_HUMAN Decreases Expression [63]
DNA mismatch repair protein Msh6 (MSH6) OT46FP09 MSH6_HUMAN Decreases Expression [13]
Death-associated protein kinase 1 (DAPK1) OTNCNUCO DAPK1_HUMAN Increases Expression [56]
Mitogen-activated protein kinase 12 (MAPK12) OTTCKE27 MK12_HUMAN Increases Activity [93]
RecQ-like DNA helicase BLM (BLM) OTEJOAJX BLM_HUMAN Decreases Expression [13]
Ataxin-1 (ATXN1) OTQF0HNR ATX1_HUMAN Decreases Expression [13]
Oxysterols receptor LXR-beta (NR1H2) OT4APA60 NR1H2_HUMAN Affects Localization [76]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [94]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [94]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Increases Expression [59]
Triosephosphate isomerase (TPI1) OT14KP4B TPIS_HUMAN Increases Phosphorylation [95]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Increases Phosphorylation [96]
DNA-dependent protein kinase catalytic subunit (PRKDC) OTJVS4EG PRKDC_HUMAN Increases Phosphorylation [71]
Protein BTG2 (BTG2) OTZF6K1H BTG2_HUMAN Increases Expression [13]
Hepcidin (HAMP) OT607RBL HEPC_HUMAN Decreases Expression [97]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [51]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [63]
Runt-related transcription factor 1 (RUNX1) OTU7J84H RUNX1_HUMAN Increases Mutagenesis [85]
Myelin transcription factor 1 (MYT1) OTC3660I MYT1_HUMAN Decreases Expression [63]
POU domain, class 5, transcription factor 1 (POU5F1) OTDHHN7O PO5F1_HUMAN Increases Expression [61]
DNA topoisomerase 2-beta (TOP2B) OTDHKQZ8 TOP2B_HUMAN Decreases Activity [98]
Histone-lysine N-methyltransferase 2A (KMT2A) OT9GLJI6 KMT2A_HUMAN Increases Cleavage [99]
Antigen peptide transporter 1 (TAP1) OTJL27PW TAP1_HUMAN Increases Expression [12]
CCAAT/enhancer-binding protein zeta (CEBPZ) OT11BATG CEBPZ_HUMAN Decreases Expression [12]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [63]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [62]
Forkhead box protein O1 (FOXO1) OTPJRB6D FOXO1_HUMAN Increases Phosphorylation [62]
Chromatin assembly factor 1 subunit A (CHAF1A) OTXSSY4H CAF1A_HUMAN Decreases Expression [13]
Oxysterols receptor LXR-alpha (NR1H3) OT54YZ9I NR1H3_HUMAN Increases Expression [76]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Phosphorylation [100]
DNA topoisomerase 3-alpha (TOP3A) OT3CKUI9 TOP3A_HUMAN Decreases Expression [13]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [63]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Increases Expression [101]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) OTXEE550 APR_HUMAN Increases Expression [53]
Protein BTG3 (BTG3) OT9ANHVT BTG3_HUMAN Decreases Expression [13]
Histone RNA hairpin-binding protein (SLBP) OTVYYQRT SLBP_HUMAN Decreases Expression [13]
Hypermethylated in cancer 1 protein (HIC1) OTI9TWY4 HIC1_HUMAN Increases Expression [102]
DNA replication licensing factor MCM6 (MCM6) OTKLIAWT MCM6_HUMAN Decreases Expression [63]
Receptor tyrosine-protein kinase erbB-4 (ERBB4) OT9L6C41 ERBB4_HUMAN Decreases Expression [57]
Neutral amino acid transporter B(0) (SLC1A5) OTE2H26Q AAAT_HUMAN Decreases Expression [13]
Mothers against decapentaplegic homolog 2 (SMAD2) OTC6VB4K SMAD2_HUMAN Increases Phosphorylation [90]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Increases Expression [103]
Cyclin-dependent kinase inhibitor 3 (CDKN3) OTBE3H07 CDKN3_HUMAN Decreases Expression [63]
Quinone oxidoreductase PIG3 (TP53I3) OTSCM68G QORX_HUMAN Increases Expression [12]
Ribosomal protein eS27-like (RPS27L) OTZWHU0N RS27L_HUMAN Increases Expression [104]
Protein MCM10 homolog (MCM10) OTV0O3JN MCM10_HUMAN Decreases Expression [13]
EPM2A-interacting protein 1 (EPM2AIP1) OT21ALNF EPMIP_HUMAN Increases Expression [12]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) OTE8GBUR RIR2B_HUMAN Increases Expression [105]
Partner and localizer of BRCA2 (PALB2) OT6DNDBG PALB2_HUMAN Decreases Expression [13]
Jouberin (AHI1) OT8K2YWY AHI1_HUMAN Increases Expression [106]
Leucine-rich repeat-containing protein 47 (LRRC47) OTSE8NAO LRC47_HUMAN Decreases Expression [13]
RelA-associated inhibitor (PPP1R13L) OTNCPLWE IASPP_HUMAN Increases Expression [107]
DNA repair and recombination protein RAD54-like (RAD54L) OTEGMAKG RAD54_HUMAN Increases Expression [14]
Cytochrome c oxidase assembly factor 7 (COA7) OTRQJYL6 COA7_HUMAN Decreases Expression [13]
Mitochondrial potassium channel (CCDC51) OTOJNHNA MITOK_HUMAN Decreases Expression [13]
Integrator complex subunit 15 (INTS15) OT3O4INM INT15_HUMAN Decreases Expression [13]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [53]
Proheparin-binding EGF-like growth factor (HBEGF) OTLU00JS HBEGF_HUMAN Increases Expression [57]
Krueppel-like factor 6 (KLF6) OTQY9S7F KLF6_HUMAN Decreases Expression [13]
Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) OTQR6ENW M3K5_HUMAN Decreases Expression [12]
Cell division control protein 6 homolog (CDC6) OTX93FE7 CDC6_HUMAN Decreases Expression [63]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [63]
SOSS complex subunit B1 (NABP2) OTQU8081 SOSB1_HUMAN Increases Acetylation [108]
Protein pelota homolog (PELO) OTF3WLIM PELO_HUMAN Decreases Expression [13]
TIMELESS-interacting protein (TIPIN) OT9PZHXV TIPIN_HUMAN Decreases Expression [13]
Cell cycle regulator of non-homologous end joining (CYREN) OT5ZL00R CYREN_HUMAN Affects Localization [109]
Caspase recruitment domain-containing protein 10 (CARD10) OT2RPM4I CAR10_HUMAN Increases Expression [59]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Decreases Expression [110]
Sulfiredoxin-1 (SRXN1) OTYDBO4L SRXN1_HUMAN Increases Expression [111]
tRNA pseudouridine(38/39) synthase (PUS3) OT6WG6M2 PUS3_HUMAN Decreases Expression [13]
Homeodomain-interacting protein kinase 2 (HIPK2) OTDB7QC3 HIPK2_HUMAN Increases Activity [81]
Serine/threonine-protein kinase PLK3 (PLK3) OT19CT2Z PLK3_HUMAN Increases Expression [12]
Transmembrane protein 185B (TMEM185B) OTGNYS0J T185B_HUMAN Decreases Expression [13]
Interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2) OT3Q11WQ I20L2_HUMAN Decreases Expression [13]
GrpE protein homolog 1, mitochondrial (GRPEL1) OT8O00YJ GRPE1_HUMAN Decreases Expression [13]
Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) OT5V52LN TNR12_HUMAN Increases Expression [59]
Programmed cell death 1 ligand 1 (CD274) OTJ0VFDL PD1L1_HUMAN Increases Expression [112]
Forkhead box protein J2 (FOXJ2) OTPT639J FOXJ2_HUMAN Decreases Expression [13]
rRNA methyltransferase 2, mitochondrial (MRM2) OTRYA1HU MRM2_HUMAN Decreases Expression [13]
DNA helicase MCM8 (MCM8) OTC93H3S MCM8_HUMAN Decreases Expression [63]
Frizzled-1 (FZD1) OTZATHVS FZD1_HUMAN Decreases Expression [13]
Calcium-binding protein 39 (CAB39) OT2CL9ST CAB39_HUMAN Decreases Expression [12]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) OT1OG4QZ AAKB1_HUMAN Increases Expression [13]
Sestrin-1 (SESN1) OTSFDZWL SESN1_HUMAN Increases Expression [13]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Decreases Response To Substance [113]
Molybdenum cofactor sulfurase (MOCOS) OT0TL3Q5 MOCOS_HUMAN Affects Response To Substance [18]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Affects Response To Substance [18]
V-type proton ATPase 116 kDa subunit a 4 (ATP6V0A4) OT149Z7Q VPP4_HUMAN Affects Response To Substance [18]
Insulin-like growth factor-binding protein 7 (IGFBP7) OT1D416P IBP7_HUMAN Affects Response To Substance [18]
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Affects Response To Substance [18]
D-3-phosphoglycerate dehydrogenase (PHGDH) OT1LMRTG SERA_HUMAN Affects Response To Substance [18]
Calcipressin-1 (RCAN1) OT1MVXC7 RCAN1_HUMAN Affects Response To Substance [18]
Melanoma antigen recognized by T-cells 1 (MLANA) OT1N2S2K MAR1_HUMAN Affects Response To Substance [18]
Serine palmitoyltransferase small subunit A (SPTSSA) OT2PNKOP SPTSA_HUMAN Affects Response To Substance [18]
Large neutral amino acids transporter small subunit 1 (SLC7A5) OT2WPVXD LAT1_HUMAN Affects Response To Substance [18]
Chitinase-3-like protein 1 (CHI3L1) OT2Z7VJH CH3L1_HUMAN Decreases Response To Substance [114]
Syncytin-2 (ERVFRD-1) OT3064D7 SYCY2_HUMAN Affects Response To Substance [18]
DNA-directed RNA polymerase I subunit RPA12 (POLR1H) OT30S3SB RPA12_HUMAN Decreases Response To Substance [115]
Protein FAM171A1 (FAM171A1) OT33BHEP F1711_HUMAN Affects Response To Substance [18]
Fatty acid CoA ligase Acsl3 (ACSL3) OT3MWER1 ACSL3_HUMAN Affects Response To Substance [18]
Platelet-derived growth factor C (PDGFC) OT3ZJ0XU PDGFC_HUMAN Affects Response To Substance [18]
Insulin receptor substrate 2 (IRS2) OT46MJBE IRS2_HUMAN Affects Response To Substance [18]
Nuclear protein 1 (NUPR1) OT4FU8C0 NUPR1_HUMAN Affects Response To Substance [18]
Proteinase-activated receptor 1 (F2R) OT4WVWBO PAR1_HUMAN Affects Response To Substance [18]
Roundabout homolog 1 (ROBO1) OT52UFVS ROBO1_HUMAN Affects Response To Substance [18]
DNA repair nuclease/redox regulator APEX1 (APEX1) OT53OI14 APEX1_HUMAN Decreases Response To Substance [116]
Lymphokine-activated killer T-cell-originated protein kinase (PBK) OT5Z27TW TOPK_HUMAN Affects Response To Substance [18]
Protein E7 (E7) OT6BIMFN VE7_HPV16 Increases ADR [52]
G-protein-signaling modulator 2 (GPSM2) OT6RPMRM GPSM2_HUMAN Affects Response To Substance [18]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Response To Substance [117]
Monocarboxylate transporter 7 (SLC16A6) OT7BIIZX MOT7_HUMAN Affects Response To Substance [18]
Homeobox protein engrailed-2 (EN2) OT7EZCM2 HME2_HUMAN Affects Response To Substance [18]
Ras-related protein Rab-17 (RAB17) OT7NBUGQ RAB17_HUMAN Affects Response To Substance [18]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Affects Response To Substance [18]
Myelin proteolipid protein (PLP1) OT8CM9CX MYPR_HUMAN Affects Response To Substance [18]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Increases Response To Substance [118]
Phosphatidylinositol 4-phosphate 5-kinase type-1 beta (PIP5K1B) OT8JQ1F7 PI51B_HUMAN Affects Response To Substance [18]
Neuronal membrane glycoprotein M6-b (GPM6B) OT8Q1582 GPM6B_HUMAN Affects Response To Substance [18]
Melanoma-associated antigen 12 (MAGEA12) OT8ULELL MAGAC_HUMAN Affects Response To Substance [18]
Solute carrier family 22 member 18 (SLC22A18) OT9C3KR4 S22AI_HUMAN Affects Response To Substance [18]
Thymosin beta-4 (TMSB4X) OT9HPLP3 TYB4_HUMAN Decreases Response To Substance [119]
Follicle-stimulating hormone receptor (FSHR) OT9MVMLI FSHR_HUMAN Increases ADR [120]
Oxidoreductase HTATIP2 (HTATIP2) OT9MZ4QO HTAI2_HUMAN Affects Response To Substance [18]
Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 (ST6GALNAC2) OT9PBQVT SIA7B_HUMAN Affects Response To Substance [18]
Splicing factor 45 (RBM17) OT9ROJCL SPF45_HUMAN Decreases Response To Substance [121]
CD44 antigen (CD44) OT9TTJ41 CD44_HUMAN Affects Response To Substance [122]
Retinoblastoma tumor suppressor (RB1) OT9VMY7B Q5J3Q9_FUNHE Increases ADR [52]
Tissue factor pathway inhibitor (TFPI) OTA0FX16 TFPI1_HUMAN Affects Response To Substance [18]
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADM) OTA4P0FC ACADM_HUMAN Affects Response To Substance [18]
POM121 and ZP3 fusion protein (POMZP3) OTAH2JOK POZP3_HUMAN Affects Response To Substance [18]
Transmembrane protein 47 (TMEM47) OTAJ4CPX TMM47_HUMAN Affects Response To Substance [18]
Glutathione S-transferase theta-2 (GSTT2) OTANW3TJ GST2_HUMAN Affects Response To Substance [18]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1) OTAYZZE6 AL3A1_HUMAN Affects Response To Substance [123]
5-hydroxytryptamine receptor 4 (HTR4) OTBIB44K 5HT4R_HUMAN Affects Response To Substance [18]
High mobility group protein HMGI-C (HMGA2) OTBMBHHL HMGA2_HUMAN Affects Response To Substance [18]
Chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGALNACT1) OTBML9D9 CGAT1_HUMAN Affects Response To Substance [18]
Microtubule-associated tumor suppressor 1 (MTUS1) OTBPALMU MTUS1_HUMAN Affects Response To Substance [18]
Cystathionine gamma-lyase (CTH) OTC90LA0 CGL_HUMAN Affects Response To Substance [18]
Melanocyte protein PMEL (PMEL) OTCDDHHM PMEL_HUMAN Affects Response To Substance [18]
BMP and activin membrane-bound inhibitor homolog (BAMBI) OTCEJ8W5 BAMBI_HUMAN Affects Response To Substance [18]
Alkaline phosphatase, germ cell type (ALPG) OTCIM29R PPBN_HUMAN Affects Response To Substance [18]
Creatine kinase U-type, mitochondrial (CKMT1A) OTCINHH5 KCRU_HUMAN Affects Response To Substance [18]
Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1) OTCJ458Q AT1A1_HUMAN Affects Response To Substance [18]
Ras-interacting protein 1 (RASIP1) OTCRY2AN RAIN_HUMAN Affects Response To Substance [18]
Collagen alpha-3(IX) chain (COL9A3) OTCUJOEK CO9A3_HUMAN Affects Response To Substance [18]
A-kinase anchor protein 12 (AKAP12) OTCVRDDX AKA12_HUMAN Affects Response To Substance [18]
Interferon-stimulated gene 20 kDa protein (ISG20) OTCWRJJW ISG20_HUMAN Affects Response To Substance [18]
Stathmin (STMN1) OTDJ4RV0 STMN1_HUMAN Affects Response To Substance [124]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Response To Substance [125]
Dickkopf-related protein 3 (DKK3) OTDU94EY DKK3_HUMAN Affects Response To Substance [18]
P protein (OCA2) OTDWIGBF P_HUMAN Affects Response To Substance [18]
Cystatin-SN (CST1) OTE4I83Q CYTN_HUMAN Affects Response To Substance [18]
Alternative prion protein (PRNP) OTE85L1Q APRIO_HUMAN Decreases Response To Substance [126]
Fructose-bisphosphate aldolase C (ALDOC) OTEC13I5 ALDOC_HUMAN Affects Response To Substance [18]
Interferon-induced transmembrane protein 1 (IFITM1) OTECO1G8 IFM1_HUMAN Affects Response To Substance [18]
Epidermal growth factor-like protein 8 (EGFL8) OTECTJ7K EGFL8_HUMAN Affects Response To Substance [18]
dTDP-D-glucose 4,6-dehydratase (TGDS) OTEOFLOS TGDS_HUMAN Affects Response To Substance [18]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases ADR [52]
Ras association domain-containing protein 1 (RASSF1) OTEZIPB7 RASF1_HUMAN Increases Response To Substance [127]
Transcription factor SOX-10 (SOX10) OTF25ULQ SOX10_HUMAN Affects Response To Substance [18]
Eukaryotic translation initiation factor 3 subunit A (EIF3A) OTFABY9G EIF3A_HUMAN Increases Response To Substance [128]
Sortilin (SORT1) OTFCQ4B1 SORT_HUMAN Affects Response To Substance [18]
Kelch-like ECH-associated protein 1 (KEAP1) OTFHOD0C KEAP1_HUMAN Increases Response To Substance [113]
Myelin basic protein (MBP) OTFZCEDB MBP_HUMAN Affects Response To Substance [18]
Protein AF1q (MLLT11) OTG5RVHC AF1Q_HUMAN Affects Response To Substance [18]
Tudor domain-containing protein 3 (TDRD3) OTG83E2C TDRD3_HUMAN Affects Response To Substance [18]
Enhancer of filamentation 1 (NEDD9) OTGCFN4M CASL_HUMAN Affects Response To Substance [18]
Squalene synthase (FDFT1) OTGDISIT FDFT_HUMAN Affects Response To Substance [18]
Voltage-gated potassium channel subunit beta-2 (KCNAB2) OTH115IE KCAB2_HUMAN Affects Response To Substance [18]
Dual specificity protein phosphatase 2 (DUSP2) OTH54FMR DUS2_HUMAN Affects Response To Substance [18]
Sigma intracellular receptor 2 (TMEM97) OTH76ZWK SGMR2_HUMAN Affects Response To Substance [18]
Melanoma-associated antigen C1 (MAGEC1) OTHMFHH8 MAGC1_HUMAN Affects Response To Substance [18]
Tribbles homolog 2 (TRIB2) OTHSX3MX TRIB2_HUMAN Affects Response To Substance [18]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Affects Response To Substance [18]
BAG family molecular chaperone regulator 2 (BAG2) OTI6LD27 BAG2_HUMAN Affects Response To Substance [18]
Nucleosome assembly protein 1-like 1 (NAP1L1) OTI7WBZV NP1L1_HUMAN Affects Response To Substance [18]
Melanoma-associated antigen 6 (MAGEA6) OTI8S0O2 MAGA6_HUMAN Affects Response To Substance [18]
Prosaposin receptor GPR37 (GPR37) OTIMDDI3 GPR37_HUMAN Affects Response To Substance [18]
Kynureninase (KYNU) OTINL2RE KYNU_HUMAN Affects Response To Substance [18]
Lysosomal acid lipase/cholesteryl ester hydrolase (LIPA) OTIOLNHE LICH_HUMAN Affects Response To Substance [18]
Baculoviral IAP repeat-containing protein 7 (BIRC7) OTITCGHB BIRC7_HUMAN Decreases Response To Substance [129]
Runt-related transcription factor 3 (RUNX3) OTITK1XD RUNX3_HUMAN Increases Response To Substance [130]
Protein S100-P (S100P) OTJCXNJG S100P_HUMAN Increases Response To Substance [131]
Osteopontin (SPP1) OTJGC23Y OSTP_HUMAN Affects Response To Substance [18]
cAMP-responsive element modulator (CREM) OTJIJ5AL CREM_HUMAN Affects Response To Substance [18]
Alpha-(1,6)-fucosyltransferase (FUT8) OTJJCVG1 FUT8_HUMAN Affects Response To Substance [18]
Trefoil factor 3 (TFF3) OTJJDRTU TFF3_HUMAN Affects Response To Substance [18]
Transcription factor-like 5 protein (TCFL5) OTJL4348 TCFL5_HUMAN Affects Response To Substance [18]
Uncharacterized protein C4orf19 (C4ORF19) OTJMU7N6 CD019_HUMAN Affects Response To Substance [18]
Sorbin and SH3 domain-containing protein 2 (SORBS2) OTJSX44Y SRBS2_HUMAN Affects Response To Substance [18]
Myc box-dependent-interacting protein 1 (BIN1) OTK8O0X8 BIN1_HUMAN Increases Response To Substance [132]
Transmembrane channel-like protein 6 (TMC6) OTKH50J4 TMC6_HUMAN Affects Response To Substance [18]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Affects Response To Substance [133]
B-cell receptor-associated protein 31 (BCAP31) OTKSACR4 BAP31_HUMAN Increases ADR [52]
Myelin P2 protein (PMP2) OTKYV2NE MYP2_HUMAN Affects Response To Substance [18]
Cytochrome P450 26A1 (CYP26A1) OTL1DFWV CP26A_HUMAN Decreases Response To Substance [134]
Histone-binding protein RBBP7 (RBBP7) OTLB56HX RBBP7_HUMAN Increases ADR [52]
Glycylpeptide N-tetradecanoyltransferase 2 (NMT2) OTLNA39Z NMT2_HUMAN Affects Response To Substance [18]
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Affects Response To Substance [18]
Homeobox protein Hox-A5 (HOXA5) OTLWGPQD HXA5_HUMAN Affects Response To Substance [18]
DNA cytosine-5)-methyltransferase 1 (DNMT1) OTM2DGTK DNMT1_HUMAN Decreases Response To Substance [135]
Lymphocyte antigen 6E (LY6E) OTMG16BZ LY6E_HUMAN Affects Response To Substance [18]
Bridging integrator 3 (BIN3) OTMIWWDW BIN3_HUMAN Affects Response To Substance [18]
Bcl-2-like protein 2 (BCL2L2) OTMKVO0J B2CL2_HUMAN Decreases Response To Substance [136]
Histone-lysine N-methyltransferase 2B (KMT2B) OTMMAZQX KMT2B_HUMAN Increases ADR [52]
Copper-transporting ATPase 1 (ATP7A) OTMR3GXP ATP7A_HUMAN Decreases Response To Substance [137]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Increases Response To Substance [138]
Protein kinase C zeta type (PRKCZ) OTN2FE42 KPCZ_HUMAN Increases Response To Substance [139]
Four and a half LIM domains protein 1 (FHL1) OTN535SU FHL1_HUMAN Affects Response To Substance [18]
Epithelial splicing regulatory protein 1 (ESRP1) OTNCS4SL ESRP1_HUMAN Affects Response To Substance [18]
Beta-secretase 2 (BACE2) OTO5YQVK BACE2_HUMAN Affects Response To Substance [18]
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B) OTOA8WU2 PDE4B_HUMAN Affects Response To Substance [18]
Hypoxanthine-guanine phosphoribosyltransferase (HPRT1) OTOEEEXG HPRT_HUMAN Increases ADR [52]
Myeloperoxidase (MPO) OTOOXLIN PERM_HUMAN Increases Metabolism [140]
Glutathione S-transferase Mu 4 (GSTM4) OTOTF8DU GSTM4_HUMAN Affects Response To Substance [18]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN) OTOWDUNT PTEN_HUMAN Increases Response To Substance [62]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Decreases Response To Substance [27]
Ras-related protein Rab-20 (RAB20) OTP9OOVS RAB20_HUMAN Affects Response To Substance [18]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C) OTPL0AI1 ABC3C_HUMAN Affects Response To Substance [18]
Epithelial membrane protein 2 (EMP2) OTPS2H0L EMP2_HUMAN Affects Response To Substance [18]
Ropporin-1A (ROPN1) OTPXKZTX ROP1A_HUMAN Affects Response To Substance [18]
Complement component 1 Q subcomponent-binding protein, mitochondrial (C1QBP) OTPYQX3K C1QBP_HUMAN Decreases Response To Substance [141]
Cyclic GMP-AMP phosphodiesterase SMPDL3A (SMPDL3A) OTQDYH8E ASM3A_HUMAN Affects Response To Substance [18]
Histone deacetylase 4 (HDAC4) OTQNGD32 HDAC4_HUMAN Affects Response To Substance [18]
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A (ANKRD28) OTRBREQ9 ANR28_HUMAN Affects Response To Substance [18]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Response To Substance [142]
Disabled homolog 2 (DAB2) OTRMQTMZ DAB2_HUMAN Affects Response To Substance [18]
Large ribosomal subunit protein eL6 (RPL6) OTRU71O4 RL6_HUMAN Decreases Response To Substance [143]
Band 4.1-like protein 3 (EPB41L3) OTS6CHG2 E41L3_HUMAN Affects Response To Substance [18]
Glutathione S-transferase Mu 1 (GSTM1) OTSBF2MO GSTM1_HUMAN Affects Response To Substance [28]
Heat shock-related 70 kDa protein 2 (HSPA2) OTSDET7B HSP72_HUMAN Affects Response To Substance [18]
MyoD family inhibitor domain-containing protein (MDFIC) OTSRYBWZ MDFIC_HUMAN Affects Response To Substance [18]
Terminal nucleotidyltransferase 5A (TENT5A) OTSYF511 TET5A_HUMAN Affects Response To Substance [18]
Collagen alpha-1(XV) chain (COL15A1) OTTFKK18 COFA1_HUMAN Affects Response To Substance [18]
Bcl-2-interacting killer (BIK) OTTH1T3D BIK_HUMAN Increases Response To Substance [144]
Serine/threonine-protein kinase Chk1 (CHEK1) OTTTI622 CHK1_HUMAN Affects Response To Substance [145]
Max-interacting protein 1 (MXI1) OTUQ9E0D MXI1_HUMAN Affects Response To Substance [18]
Calcium-dependent secretion activator 2 (CADPS2) OTV1FW0M CAPS2_HUMAN Affects Response To Substance [18]
Forkhead box protein F2 (FOXF2) OTV20NGX FOXF2_HUMAN Affects Response To Substance [18]
Metastasis-associated in colon cancer protein 1 (MACC1) OTV3DLX0 MACC1_HUMAN Increases ADR [120]
Glutathione S-transferase LANCL1 (LANCL1) OTVCMZXB LANC1_HUMAN Affects Response To Substance [18]
Matrilin-2 (MATN2) OTVDR68G MATN2_HUMAN Affects Response To Substance [18]
Microtubule-actin cross-linking factor 1, isoforms 1/2/3/4/5 (MACF1) OTVIHD77 MACF1_HUMAN Affects Response To Substance [18]
Poly polymerase tankyrase-1 (TNKS) OTVOUTPX TNKS1_HUMAN Affects Response To Substance [18]
Ensconsin (MAP7) OTVSSJ33 MAP7_HUMAN Affects Response To Substance [18]
Integrin beta-3 (ITGB3) OTWCK1K6 ITB3_HUMAN Increases Response To Substance [146]
N-myc proto-oncogene protein (MYCN) OTWD33K1 MYCN_HUMAN Decreases Response To Substance [147]
Sorbin and SH3 domain-containing protein 1 (SORBS1) OTWH8762 SRBS1_HUMAN Affects Response To Substance [18]
Anamorsin (CIAPIN1) OTWS90F9 CPIN1_HUMAN Decreases Response To Substance [148]
Inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) OTX7MWW1 ITPR1_HUMAN Affects Response To Substance [18]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) OTX8L3M5 SAHH2_HUMAN Affects Response To Substance [18]
Long-chain fatty acid transport protein 3 (SLC27A3) OTXB60L7 S27A3_HUMAN Affects Response To Substance [18]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Affects Response To Substance [149]
Estrogen receptor beta (ESR2) OTXNR2WQ ESR2_HUMAN Increases Response To Substance [150]
Coiled-coil domain-containing protein 6 (CCDC6) OTXRQDYG CCDC6_HUMAN Decreases Response To Substance [151]
Arginine vasopressin-induced protein 1 (AVPI1) OTXSBR60 AVPI1_HUMAN Affects Response To Substance [18]
Carbamoyl-phosphate synthase , mitochondrial (CPS1) OTXV8NSR CPSM_HUMAN Affects Response To Substance [18]
Peripheral myelin protein 22 (PMP22) OTXWYWCZ PMP22_HUMAN Affects Response To Substance [18]
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related (HMG20B) OTY94WRA HM20B_HUMAN Affects Response To Substance [18]
Protein Niban 1 (NIBAN1) OTYOLI12 NIBA1_HUMAN Affects Response To Substance [18]
LIM and calponin homology domains-containing protein 1 (LIMCH1) OTYPC4XA LIMC1_HUMAN Affects Response To Substance [18]
Galectin-3 (LGALS3) OTYQT0ZI LEG3_HUMAN Affects Response To Substance [18]
L-dopachrome tautomerase (DCT) OTYVNTBG TYRP2_HUMAN Affects Response To Substance [18]
PRA1 family protein 3 (ARL6IP5) OTYZ6BEQ PRAF3_HUMAN Increases Response To Substance [152]
DNA (DNMT3B) OTZ0JCNP DNM3B_HUMAN Decreases Response To Substance [135]
Calcitonin (CALCA) OTZ11LHB CALC_HUMAN Decreases Response To Substance [153]
Hephaestin (HEPH) OTZ2F15Z HEPH_HUMAN Affects Response To Substance [18]
Complement decay-accelerating factor (CD55) OTZ3HWTO DAF_HUMAN Affects Response To Substance [18]
Tissue factor pathway inhibitor 2 (TFPI2) OTZCRWOR TFPI2_HUMAN Affects Response To Substance [18]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Affects Response To Substance [18]
Suppressor of tumorigenicity 7 protein (ST7) OTZG8RC6 ST7_HUMAN Affects Response To Substance [18]
UPF0489 protein C5orf22 (C5ORF22) OTZN0DCX CE022_HUMAN Affects Response To Substance [18]
Alkaline phosphatase, placental type (ALPP) OTZU4G9W PPB1_HUMAN Affects Response To Substance [18]
Drebrin (DBN1) OTZVKG8A DREB_HUMAN Affects Response To Substance [18]
------------------------------------------------------------------------------------
⏷ Show the Full List of 475 DOT(s)
Indication(s) of GSK525762
Disease Entry ICD 11 Status REF
Haematological malignancy 2B33.Y Phase 1 [6]
Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
GSK525762 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bromodomain-containing protein 4 (BRD4) TTRA6BO BRD4_HUMAN Modulator [155]
Bromodomain and extraterminal domain protein (BET) TTE4BSY NOUNIPROTAC Inhibitor [6]
------------------------------------------------------------------------------------
GSK525762 Interacts with 11 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Apolipoprotein A-I (APOA1) OT5THARI APOA1_HUMAN Increases Expression [156]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Expression [157]
Trefoil factor 1 (TFF1) OTCYQH4F TFF1_HUMAN Decreases Expression [157]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [157]
Protein-lysine 6-oxidase (LOX) OT1C2HIU LYOX_HUMAN Decreases Expression [154]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [158]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [158]
Carbonic anhydrase 9 (CA9) OTNA51XT CAH9_HUMAN Decreases Expression [154]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) OT25JBA3 F263_HUMAN Increases Expression [154]
Protein GREB1 (GREB1) OTU6ZA26 GREB1_HUMAN Decreases Expression [157]
Endothelial PAS domain-containing protein 1 (EPAS1) OTRE3O8U EPAS1_HUMAN Increases Expression [154]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCKHRTU NCIH1650 Investigative [1]
Adenocarcinoma DC7SDN6 NCIH520 Investigative [1]
Breast and ovarian cancer syndrome DCDPMRZ UWB1289 Investigative [159]
Carcinoma DCAL2QA MDAMB436 Investigative [159]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Etoposide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6815).
4 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 075635.
5 ClinicalTrials.gov (NCT04356690) Etoposide in Patients With COVID-19 Infection. U.S. National Institutes of Health.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7033).
8 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
9 Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. J Biol Chem. 2007 Oct 12;282(41):29847-54.
10 Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
11 Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells. Arch Toxicol. 2018 Apr;92(4):1507-1524.
12 Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
13 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
14 New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines. Breast Cancer Res. 2006;8(1):R1. doi: 10.1186/bcr1362. Epub 2005 Dec 9.
15 Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells. Basic Clin Pharmacol Toxicol. 2015 Dec;117(6):383-91. doi: 10.1111/bcpt.12425. Epub 2015 Jun 30.
16 Identification of XAF1-MT2A mutual antagonism as a molecular switch in cell-fate decisions under stressful conditions. Proc Natl Acad Sci U S A. 2017 May 30;114(22):5683-5688. doi: 10.1073/pnas.1700861114. Epub 2017 May 15.
17 Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway. Blood. 2008 Apr 15;111(8):4365-74. doi: 10.1182/blood-2007-08-106336. Epub 2008 Feb 12.
18 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
19 Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate. 2005 Jan 1;62(1):61-8. doi: 10.1002/pros.20117.
20 Werner's syndrome lymphoblastoid cells are hypersensitive to topoisomerase II inhibitors in the G2 phase of the cell cycle. Mutat Res. 2000 Mar 20;459(2):123-33. doi: 10.1016/s0921-8777(99)00065-8.
21 Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma. Eur J Cancer. 2011 Sep;47(13):2068-76. doi: 10.1016/j.ejca.2011.04.021. Epub 2011 May 18.
22 Human mitochondrial thioredoxin. Involvement in mitochondrial membrane potential and cell death. J Biol Chem. 2002 Sep 6;277(36):33249-57. doi: 10.1074/jbc.M203036200. Epub 2002 Jun 21.
23 An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. Cancer Res. 2002 Oct 15;62(20):5888-96.
24 A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA. PLoS Med. 2008 May 20;5(5):e94. doi: 10.1371/journal.pmed.0050094.
25 Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2. Biochim Biophys Acta. 2014 Feb;1843(2):387-97. doi: 10.1016/j.bbamcr.2013.10.015. Epub 2013 Oct 31.
26 The Wnt signaling pathway regulates Nalm-16 b-cell precursor acute lymphoblastic leukemic cell line survival and etoposide resistance. Biomed Pharmacother. 2010 Jan;64(1):63-72. doi: 10.1016/j.biopha.2009.09.005. Epub 2009 Oct 27.
27 Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst. 2000 Jan 5;92(1):18-23. doi: 10.1093/jnci/92.1.18.
28 Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005 Jun 15;105(12):4752-8. doi: 10.1182/blood-2004-11-4544. Epub 2005 Feb 15.
29 Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
30 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
31 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
32 Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
33 Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
34 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
35 Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.
36 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
37 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
38 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
39 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
40 Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
41 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
42 Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
43 Development of in vitro 3D cell model from hepatocellular carcinoma (HepG2) cell line and its application for genotoxicity testing. Arch Toxicol. 2019 Nov;93(11):3321-3333. doi: 10.1007/s00204-019-02576-6. Epub 2019 Sep 21.
44 O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994 Feb;45(2):352-8.
45 The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther. 2000 Aug;294(2):480-7.
46 Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines. Int J Biochem Mol Biol. 2016 Aug 5;7(2):27-47. eCollection 2016.
47 Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 2005 May 14;11(18):2748-53. doi: 10.3748/wjg.v11.i18.2748.
48 Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2. J Med Invest. 2005 Feb;52(1-2):41-8. doi: 10.2152/jmi.52.41.
49 Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines. Jpn J Cancer Res. 2001 Oct;92(10):1133-7. doi: 10.1111/j.1349-7006.2001.tb01069.x.
50 Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
51 Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
52 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
53 Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol Cancer. 2011 Jul 31;10:95. doi: 10.1186/1476-4598-10-95.
54 Effect of functionalized and non-functionalized nanodiamond on the morphology and activities of antioxidant enzymes of lung epithelial cells (A549). Chem Biol Interact. 2014 Oct 5;222:135-47.
55 Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol. 2005 Jul;25(13):5404-16. doi: 10.1128/MCB.25.13.5404-5416.2005.
56 Transcriptional repression of IKK by p53 in arsenite-induced GADD45 accumulation and apoptosis. Oncogene. 2019 Jan;38(5):731-746. doi: 10.1038/s41388-018-0478-7. Epub 2018 Sep 3.
57 The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. Mol Cell Biochem. 2004 May;260(1-2):129-35. doi: 10.1023/b:mcbi.0000026063.96267.98.
58 Profiling dose-dependent activation of p53-mediated signaling pathways by chemicals with distinct mechanisms of DNA damage. Toxicol Sci. 2014 Nov;142(1):56-73. doi: 10.1093/toxsci/kfu153. Epub 2014 Jul 30.
59 Estrogen regulation of apoptosis in osteoblasts. Physiol Behav. 2010 Feb 9;99(2):181-5. doi: 10.1016/j.physbeh.2009.04.025. Epub 2009 May 5.
60 Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer. 2003 Dec 20;107(6):929-40. doi: 10.1002/ijc.11503.
61 Lysosome Fe(2+) release is responsible for etoposide- and cisplatin-induced stemness of small cell lung cancer cells. Environ Toxicol. 2021 Aug;36(8):1654-1663. doi: 10.1002/tox.23161. Epub 2021 May 10.
62 Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer. 2008 Jan 15;122(2):433-43. doi: 10.1002/ijc.23049.
63 Responses of genes involved in cell cycle control to diverse DNA damaging chemicals in human lung adenocarcinoma A549 cells. Cancer Cell Int. 2005 Aug 24;5:28. doi: 10.1186/1475-2867-5-28.
64 Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
65 Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2. J Med Chem. 2011 Jan 27;54(2):580-90. doi: 10.1021/jm101150b. Epub 2010 Dec 27.
66 (-)-Xanthatin induces the prolonged expression of c-Fos through an N-acetyl-L-cysteine (NAC)-sensitive mechanism in human breast cancer MDA-MB-231 cells. J Toxicol Sci. 2013;38(4):547-57. doi: 10.2131/jts.38.547.
67 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
68 Basal and UV-induced MMP-1 expression are inhibited by p53 in human dermal fibroblasts. Exp Dermatol. 2008 Nov;17(11):939-45. doi: 10.1111/j.1600-0625.2008.00729.x. Epub 2008 Jun 14.
69 2,3,7,8-tetrachlorodibenzo-p-dioxin counteracts the p53 response to a genotoxicant by upregulating expression of the metastasis marker agr2 in the hepatocarcinoma cell line HepG2. Toxicol Sci. 2010 Jun;115(2):501-12. doi: 10.1093/toxsci/kfq082. Epub 2010 Mar 18.
70 cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells. J Cell Sci. 1998 Mar;111 ( Pt 5):637-44. doi: 10.1242/jcs.111.5.637.
71 DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation. Cancer Sci. 2007 Jun;98(6):858-63. doi: 10.1111/j.1349-7006.2007.00476.x. Epub 2007 Apr 18.
72 [Influence of HMGB1/MAPK/m-TOR signaling pathway on cell autophagy and chemotherapy resistance in K562 cells]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016 Oct 28;41(10):1016-1023. doi: 10.11817/j.issn.1672-7347.2016.10.002.
73 p21Cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J Biol Chem. 2003 Jun 27;278(26):23360-8. doi: 10.1074/jbc.M300771200. Epub 2003 Apr 10.
74 Expression and release of chemokines associated with apoptotic cell death in human promonocytic U937 cells and peripheral blood mononuclear cells. Eur J Immunol. 1999 Oct;29(10):3225-35. doi: 10.1002/(SICI)1521-4141(199910)29:10<3225::AID-IMMU3225>3.0.CO;2-0.
75 Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. J Cell Physiol. 2008 Dec;217(3):569-76. doi: 10.1002/jcp.21565.
76 Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II. J Biol Chem. 2015 Jun 5;290(23):14418-29. doi: 10.1074/jbc.M115.643015. Epub 2015 Apr 25.
77 Tumor protein translationally controlled 1 is a p53 target gene that promotes cell survival. Cell Cycle. 2013 Jul 15;12(14):2321-8. doi: 10.4161/cc.25404.
78 The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces. Br J Haematol. 2003 Jan;120(2):315-24. doi: 10.1046/j.1365-2141.2003.03971.x.
79 Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. doi: 10.1093/jnci/djs002. Epub 2012 Feb 1.
80 Specific inhibition of rRNA transcription and dynamic relocation of fibrillarin induced by mercury. Exp Cell Res. 2000 Aug 25;259(1):225-38. doi: 10.1006/excr.2000.4923.
81 Regulation of genotoxic stress response by homeodomain-interacting protein kinase 2 through phosphorylation of cyclic AMP response element-binding protein at serine 271. Mol Biol Cell. 2010 Aug 15;21(16):2966-74. doi: 10.1091/mbc.E10-01-0015. Epub 2010 Jun 23.
82 Two distinct phases of virus-induced nuclear factor kappa B regulation enhance tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in virus-infected cells. J Biol Chem. 2003 May 16;278(20):18092-100. doi: 10.1074/jbc.M300265200. Epub 2003 Mar 13.
83 MAP kinase-signaling controls nuclear translocation of tripeptidyl-peptidase II in response to DNA damage and oxidative stress. Biochem Biophys Res Commun. 2010 Aug 27;399(3):324-30. doi: 10.1016/j.bbrc.2010.06.133. Epub 2010 Jul 17.
84 Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. Clin Biochem. 2005 Jan;38(1):50-7. doi: 10.1016/j.clinbiochem.2004.09.012.
85 "Exposure to the insecticides permethrin and malathion induces leukemia and lymphoma-associated gene aberrations in vitro". Toxicol In Vitro. 2017 Oct;44:17-26. doi: 10.1016/j.tiv.2017.06.013. Epub 2017 Jun 15.
86 CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway. Chem Biol Interact. 2016 Dec 25;260:1-12. doi: 10.1016/j.cbi.2016.10.014. Epub 2016 Oct 18.
87 Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res. 2004 Jan;2(1):53-61.
88 A molecular beacon approach to detecting RAD52 expression in response to DNA damage in human cells. Toxicol In Vitro. 2010 Mar;24(2):652-60. doi: 10.1016/j.tiv.2009.09.019. Epub 2009 Sep 30.
89 Nitric oxide inhibits apoptosis via AP-1-dependent CD95L transactivation. Cancer Res. 2000 May 1;60(9):2377-83.
90 Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
91 DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes. Int J Mol Med. 2006 Dec;18(6):1081-7.
92 Protein kinase Cdelta stimulates proteasome-dependent degradation of C/EBPalpha during apoptosis induction of leukemic cells. PLoS One. 2009 Aug 7;4(8):e6552. doi: 10.1371/journal.pone.0006552.
93 Phosphorylation and stabilization of topoisomerase II protein by p38 mitogen-activated protein kinase sensitize breast cancer cells to its poisons. J Biol Chem. 2011 Oct 14;286(41):35883-35890. doi: 10.1074/jbc.M111.229260. Epub 2011 Aug 30.
94 Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma. Clin Cancer Res. 2007 Dec 1;13(23):7012-21. doi: 10.1158/1078-0432.CCR-06-2891.
95 Functional inactivation of triosephosphate isomerase through phosphorylation during etoposide-induced apoptosis in HeLa cells: potential role of Cdk2. Toxicology. 2010 Dec 5;278(2):224-8. doi: 10.1016/j.tox.2010.02.005. Epub 2010 Feb 10.
96 NF-B1 p50 promotes p53 protein translation through miR-190 downregulation of PHLPP1. Oncogene. 2014 Feb 20;33(8):996-1005. doi: 10.1038/onc.2013.8. Epub 2013 Feb 11.
97 A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. Exp Hematol. 2015 May;43(5):404-413.e5. doi: 10.1016/j.exphem.2015.01.005. Epub 2015 Jan 26.
98 Chlorpyrifos Induces MLL Translocations Through Caspase 3-Dependent Genomic Instability and Topoisomerase II Inhibition in Human Fetal Liver Hematopoietic Stem Cells. Toxicol Sci. 2015 Oct;147(2):588-606. doi: 10.1093/toxsci/kfv153. Epub 2015 Jul 20.
99 The broken MLL gene is frequently located outside the inherent chromosome territory in human lymphoid cells treated with DNA topoisomerase II poison etoposide. PLoS One. 2013 Sep 25;8(9):e75871. doi: 10.1371/journal.pone.0075871. eCollection 2013.
100 Amsacrine downregulates BCL2L1 expression and triggers apoptosis in human chronic myeloid leukemia cells through the SIDT2/NOX4/ERK/HuR pathway. Toxicol Appl Pharmacol. 2023 Sep 1;474:116625. doi: 10.1016/j.taap.2023.116625. Epub 2023 Jul 13.
101 Translation of cellular inhibitor of apoptosis protein 1 (c-IAP1) mRNA is IRES mediated and regulated during cell stress. RNA. 2004 Mar;10(3):469-81. doi: 10.1261/rna.5156804.
102 The tumor suppressor gene hypermethylated in cancer 1 is transcriptionally regulated by E2F1. Mol Cancer Res. 2009 Jun;7(6):916-22. doi: 10.1158/1541-7786.MCR-08-0359. Epub 2009 Jun 2.
103 Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2. Cancer Sci. 2008 Aug;99(8):1693-8. doi: 10.1111/j.1349-7006.2008.00867.x.
104 Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress. Cancer Res. 2007 Dec 1;67(23):11317-26. doi: 10.1158/0008-5472.CAN-07-1088.
105 Validation of a genotoxicity test based on p53R2 gene expression in human lymphoblastoid cells. Mutat Res. 2011 Sep 18;724(1-2):76-85. doi: 10.1016/j.mrgentox.2011.06.003. Epub 2011 Jun 17.
106 [Expression and function of Ahi-1 gene in Jurkat cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Apr;17(2):445-9.
107 Expression of the RAI gene is conducive to apoptosis: studies of induction and interference. Exp Cell Res. 2007 Jul 15;313(12):2611-21. doi: 10.1016/j.yexcr.2007.05.006. Epub 2007 May 22.
108 Acetylation-dependent function of human single-stranded DNA binding protein 1. Nucleic Acids Res. 2015 Sep 18;43(16):7878-87. doi: 10.1093/nar/gkv707. Epub 2015 Jul 13.
109 A human short open reading frame (sORF)-encoded polypeptide that stimulates DNA end joining. J Biol Chem. 2014 Apr 18;289(16):10950-10957. doi: 10.1074/jbc.C113.533968. Epub 2014 Mar 7.
110 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
111 Comprehensive Landscape of Nrf2 and p53 Pathway Activation Dynamics by Oxidative Stress and DNA Damage. Chem Res Toxicol. 2017 Apr 17;30(4):923-933. doi: 10.1021/acs.chemrestox.6b00322. Epub 2016 Dec 16.
112 Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol. 2008 Mar;45(5):1470-6. doi: 10.1016/j.molimm.2007.08.013. Epub 2007 Oct 24.
113 Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells. Toxicol Appl Pharmacol. 2016 Feb 1;292:1-7. doi: 10.1016/j.taap.2015.12.008. Epub 2015 Dec 18.
114 CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer. 2011 Mar 15;128(6):1316-26. doi: 10.1002/ijc.25466.
115 Overexpression of ZNRD1 promotes multidrug-resistant phenotype of gastric cancer cells through upregulation of P-glycoprotein. Cancer Biol Ther. 2004 Apr;3(4):377-81. doi: 10.4161/cbt.3.4.724. Epub 2004 Apr 17.
116 Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene. 2011 Jan 27;30(4):482-93. doi: 10.1038/onc.2010.435. Epub 2010 Sep 20.
117 CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer. 2006 Mar 18;6:75. doi: 10.1186/1471-2407-6-75.
118 Selective cell death of oncogenic Akt-transduced brain cancer cells by etoposide through reactive oxygen species mediated damage. Mol Cancer Ther. 2007 Aug;6(8):2178-87. doi: 10.1158/1535-7163.MCT-07-0111.
119 Overexpression of thymosin beta-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating Fas and upregulating Survivin expression, respectively. Carcinogenesis. 2006 May;27(5):936-44. doi: 10.1093/carcin/bgi316. Epub 2005 Dec 19.
120 Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
121 Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. doi: 10.1158/0008-5472.CAN-03-3675.
122 CD44 promotes resistance to apoptosis in human colon cancer cells. Exp Mol Pathol. 2004 Aug;77(1):18-25. doi: 10.1016/j.yexmp.2004.03.002.
123 Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells. J Biol Chem. 2005 Jul 29;280(30):27998-8006. doi: 10.1074/jbc.M503698200. Epub 2005 May 19.
124 Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Cancer Ther. 2006 Dec;5(12):3248-57. doi: 10.1158/1535-7163.MCT-06-0227.
125 Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer. 2007 Dec 1;121(11):2387-94. doi: 10.1002/ijc.22977.
126 Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR. Int J Cancer. 2005 Jan 10;113(2):213-20. doi: 10.1002/ijc.20570.
127 RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines. Neuro Oncol. 2011 Dec;13(12):1265-76. doi: 10.1093/neuonc/nor129. Epub 2011 Aug 31.
128 Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair. Clin Cancer Res. 2011 Jul 1;17(13):4600-9. doi: 10.1158/1078-0432.CCR-10-2591. Epub 2011 May 24.
129 Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis. Cell Mol Life Sci. 2007 May;64(9):1137-44. doi: 10.1007/s00018-007-6510-7.
130 Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int J Cancer. 2005 Aug 10;116(1):155-60. doi: 10.1002/ijc.20919.
131 S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3. Oncol Rep. 2008 Aug;20(2):325-32.
132 c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci Signal. 2011 Mar 29;4(166):ra19. doi: 10.1126/scisignal.2001556.
133 Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
134 Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol Pharmacol. 2005 May;67(5):1808-17. doi: 10.1124/mol.104.005769. Epub 2005 Feb 9.
135 DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells. Mol Cancer Res. 2008 Feb;6(2):243-9. doi: 10.1158/1541-7786.MCR-07-0373.
136 Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 2004 Feb 15;64(4):1403-10. doi: 10.1158/0008-5472.can-3263-2.
137 Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res. 2007 May 15;67(10):4860-8. doi: 10.1158/0008-5472.CAN-06-3096.
138 Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res. 2005 Oct 1;65(19):8628-34. doi: 10.1158/0008-5472.CAN-05-1059.
139 4-benzimidazolyl-3-phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKC. J Med Chem. 2011 Oct 13;54(19):6714-23. doi: 10.1021/jm2005892. Epub 2011 Sep 14.
140 Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells. Chem Res Toxicol. 2006 Jul;19(7):937-43. doi: 10.1021/tx0600595.
141 [Expression of C1QBP gene and its correlation with drug resistance in human resistance choriocarcinoma cell line]. Zhonghua Fu Chan Ke Za Zhi. 2014 Aug;49(8):616-20.
142 Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood. 2001 Aug 1;98(3):805-13. doi: 10.1182/blood.v98.3.805.
143 Regulation of multidrug resistance by ribosomal protein l6 in gastric cancer cells. Cancer Biol Ther. 2005 Feb;4(2):242-7. doi: 10.4161/cbt.4.2.1477. Epub 2005 Feb 20.
144 Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk / Bik. Oncogene. 2005 Nov 10;24(49):7369-80. doi: 10.1038/sj.onc.1208890.
145 Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin Cancer Res. 2008 Aug 15;14(16):5131-41. doi: 10.1158/1078-0432.CCR-08-0304.
146 Pro-apoptotic role of integrin 3 in glioma cells. J Neurochem. 2011 May;117(3):494-503. doi: 10.1111/j.1471-4159.2011.07219.x. Epub 2011 Mar 15.
147 Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells. Oncogene. 1999 Apr 29;18(17):2777-82. doi: 10.1038/sj.onc.1202859.
148 [Reversal of multidrug resistance of gastric cancer cells by down-regulation of CIAPIN1 with CIAPIN1 siRNA]. Mol Biol (Mosk). 2008 Jan-Feb;42(1):102-9.
149 Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther. 2005 Jan;12(1):90-100. doi: 10.1038/sj.cgt.7700775.
150 Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G?/M checkpoint signaling. Breast Cancer Res Treat. 2011 Jun;127(2):417-27. doi: 10.1007/s10549-010-1011-z. Epub 2010 Jul 10.
151 Loss of CCDC6 affects cell cycle through impaired intra-S-phase checkpoint control. PLoS One. 2012;7(2):e31007. doi: 10.1371/journal.pone.0031007. Epub 2012 Feb 17.
152 JWA sensitizes P-glycoprotein-mediated drug-resistant choriocarcinoma cells to etoposide via JNK and mitochondrial-associated signal pathway. J Toxicol Environ Health A. 2009;72(11-12):774-81. doi: 10.1080/15287390902841649.
153 Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway. Cancer Biol Ther. 2005 Nov;4(11):1226-33. doi: 10.4161/cbt.4.11.2093. Epub 2005 Nov 5.
154 The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. Oncogene. 2017 Jan 5;36(1):122-132. doi: 10.1038/onc.2016.184. Epub 2016 Jun 13.
155 Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
156 Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38.
157 An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul;24(7):809-19. doi: 10.1038/cr.2014.71. Epub 2014 May 30.
158 MCM5 as a target of BET inhibitors in thyroid cancer cells. Endocr Relat Cancer. 2016 Apr;23(4):335-47. doi: 10.1530/ERC-15-0322. Epub 2016 Feb 24.
159 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.